These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32284682)

  • 21. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
    Miller JE; Korn D; Ross JS
    BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator.
    Idänpään-Heikkilä JE
    Ann Med; 1994 Apr; 26(2):89-94. PubMed ID: 8024733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continued investigator engagement: Reasons principal investigators conduct multiple FDA-regulated drug trials.
    Dombeck CB; Hinkley T; Fordyce CB; Blanchard K; Roe MT; Corneli A
    Contemp Clin Trials Commun; 2020 Mar; 17():100502. PubMed ID: 31890985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations.
    Jung M; Swann RM; Anantha MS; Jamali F
    Ther Innov Regul Sci; 2021 Sep; 55(5):907-917. PubMed ID: 34101151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections.
    Kim J; Singh H; Ayalew K; Borror K; Campbell M; Johnson LL; Karesh A; Khin NA; Less JR; Menikoff J; Minasian L; Mitchell SA; Papadopoulos EJ; Piekarz RL; Prohaska KA; Thompson S; Sridhara R; Pazdur R; Kluetz PG
    Clin Cancer Res; 2018 Apr; 24(8):1780-1784. PubMed ID: 29237718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Good clinical practice regulatory inspections: Lessons for Indian investigator sites.
    Marwah R; Van de Voorde K; Parchman J
    Perspect Clin Res; 2010 Oct; 1(4):151-5. PubMed ID: 21350732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. US Food and Drug Administration Clinical Investigator Inspections.
    Buchmeier AD
    Semin Oncol Nurs; 2020 Apr; 36(2):151000. PubMed ID: 32253049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A clinical trial primer: historical perspective and modern implementation.
    Karsh LI
    Urol Oncol; 2012; 30(4 Suppl):S28-32. PubMed ID: 22795078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA oversight of NSIGHT genomic research: the need for an integrated systems approach to regulation.
    Milko LV; Chen F; Chan K; Brower AM; Agrawal PB; Beggs AH; Berg JS; Brenner SE; Holm IA; Koenig BA; Parad RB; Powell CM; Kingsmore SF
    NPJ Genom Med; 2019; 4():32. PubMed ID: 31839987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The investigator-sponsored IND in clinical trials.
    Haakenson C; Fye CL; Sather MR; Toussaint DJ
    Control Clin Trials; 1987 Jun; 8(2):101-9. PubMed ID: 3608504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA's conduct, review, and evaluation of inspections of clinical investigators.
    Turner G; Lisook AB; Delman DP
    Drug Inf J; 1987; 21(2):117-25. PubMed ID: 10282112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Questions of scientific responsibility: the Baltimore case.
    Lang S
    Ethics Behav; 1993; 3(1):3-72. PubMed ID: 11653082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. So You Want to Be a Principal Investigator.
    Saleh M; Naik G
    J Oncol Pract; 2018 Jun; 14(6):e384-e392. PubMed ID: 29750578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors.
    Hirsch L
    Curr Med Res Opin; 2008 Jun; 24(6):1683-9. PubMed ID: 18462565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of clinical trials in developing countries.
    de Maar EW; Chaudhury RR; Kofi Ekue JM; Granata F; Walker AN
    J Int Med Res; 1983; 11(1):1-5. PubMed ID: 6832461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The responsibilities of investigators, monitors, and sponsors of clinical studies supporting new animal drug applications. Center for Veterinary Medicine, FDA.
    Schoenemann HM; McCormack JF; Smedley KO
    J Anim Sci; 1995 Feb; 73(2):606-13; discussion 612-3. PubMed ID: 7601797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Responsibilities of animal scientists and drug sponsors when conducting research with investigational new animal drugs.
    Knight WM
    J Anim Sci; 1987 Aug; 65(2):581-3. PubMed ID: 3624101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.